-

PerkinElmer Introduces AuroFlow® AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities

Features water-based testing strips and handheld reader delivering convenience and accuracy

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched its AuroFlow® AQ Mycotoxin Platform. This new solution includes strip test versions for Total Aflatoxin, Deoxynivalenol (DON), Fumonisin, Ochratoxin A, Zearalenone and T-2/HT-2. Lab professionals, technicians and farmers can utilize this platform for first-round screening of corn and wheat for key, regulated mycotoxin compounds with convenience, speed and accuracy.

The expanded offering builds on PerkinElmer’s existing AuroFlow AQ Afla strip test (for B1, B2, G1, G2) and leverages the PerkinElmer QuickSTAR™ Horizon strip reader. Results are delivered in six minutes or less, detection levels as low as 2 ppb, depending on the mycotoxin being detected.

PerkinElmer’s AuroFlow AQ Mycotoxin kits use a single-step, water-based extraction method with lateral flow testing at room temperature. This enables safer and easier sampling and removes the need for incubators and centrifuges during analysis. The handheld reader is battery operated and ruggedized for portable testing. Once results are viewed on the reader’s menu-driven, color touchscreen, the information is stored for future access and archiving, creating clear and accurate audit trails.

The new kits are part of PerkinElmer’s comprehensive portfolio of solutions for grain toxin testing workflows which span from screening tools to confirmatory analyses with instruments such as the QSight® 400 Series Triple Quad Mass Spectrometer. They also complement the company’s overall food safety and quality testing offerings which include instruments, software, testing kits, reagents and services for a variety of food matrixes.

“Mycotoxins are a very prevalent issue for the grain industry, with multiple forms often being seen in single samples,” said Greg Sears, vice president and general manager, Food, PerkinElmer. “With the 2020 harvest rapidly approaching, it is essential that food safety professionals have innovative testing options to help ensure the safety of corn and wheat entering the global food chain. Our mycotoxin solutions help them detect and fight these unwanted and highly regulated contaminants from the grain elevator to the lab.”

To learn more please visit https://www.perkinelmer.com/product/auroflow-aq-afla-strip-test-food-1413-01 and https://www.perkinelmer.com/category/food-safety-quality.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

Jennifer McNeil
jennifer.mcneil@perkinelmer.com
+1-508-361-5901

PerkinElmer

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
PerkinElmer’s new AuroFlow® AQ Mycotoxin Platform tests for key, regulated mycotoxins in corn and wheat samples with speed, accuracy and convenience.
Release Versions

Contacts

Jennifer McNeil
jennifer.mcneil@perkinelmer.com
+1-508-361-5901

More News From PerkinElmer

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird’s 2026 Global Healthcare Conference Tuesday, September...

Revvity Announces Financial Results for the Second Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related...
Back to Newsroom